YSYujun Shen

Yujun Shen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yujun Shen has a total of 185 co-authors. Here are the top co-authors by number of shared publications:

  • Ying Yu

    Department of Pharmacology, Tianjin Key Laboratory of Inflammatory Biology, Center for Cardiovascular Diseases, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, State Key Laboratory of Experimental Hematology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China

    18 shared publications
  • Yuanyang Wang

    Department of Pharmacology, Tianjin Key Laboratory of Inflammatory Biology, Center for Cardiovascular Diseases, Haihe Laboratory of Cell Ecosystem, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), The Province and Ministry Co‐sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Experimental Hematology, School of Basic Medical Sciences Tianjin Medical University Tianjin 300070 China

    7 shared publications
  • Guilin Chen

    Tianjin Key Laboratory of Inflammatory Biology Center for Cardiovascular Diseases Key Laboratory of Immune Microenvironment and Disease (Ministry of Education) Department of Pharmacology The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics School of Basic Medical Sciences Tianjin Medical University Tianjin China

    5 shared publications
  • Jian Zhang

    Pharmacology and Tianjin Key Laboratory of Inflammatory Biology, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China (D.J., J.L., G.C., Y.Y., J.Z., Y. Shen)

    5 shared publications
  • Qian Liu

    Department of Pharmacology, Tianjin Key Laboratory of Inflammatory Biology, Center for Cardiovascular Diseases, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, State Key Laboratory of Experimental Hematology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China

    5 shared publications
  • Shengkai Zuo

    Department of Pharmacology, Tianjin Key Laboratory of Inflammatory Biology, Center for Cardiovascular Diseases, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China

    5 shared publications

Latest Publications

  • Open Access

    Spatiotemporally programmed biomimetic liposome coordinates vascular and immune modulation in pulmonary arterial hypertension

    by Jingsong Cao, Yuanyuan Cheng, Yuhan Wang, Ting Pan, Qi He, Yuxin Ma, Jiong-Wei Wang, Yinsong Wang, Ying Yu, Yujun Shen

  • Open Access

    Two‐Point Change Patterns of LDL‐Cholesterol and hs‐CRP and Risk of Major Adverse Cardiovascular Events in Middle‐Aged and Older Chinese Adults: A Prospective Cohort Study

    by Jiayin Guo, Bin Zhao, Zongwei Liu, Zhian Liang, Yujun Shen, Xiangchen Dai

    Background and Aims: The associations of two‐point change patterns of low‐density lipoprotein cholesterol (LDL‐C) and high‐sensitivity C‐reactive protein (hs‐CRP) with major adverse cardiovascular events (MACE) remain underexplored, particularly in Chinese populations. This study aimed to identify LDL‐C and hs‐CRP change patterns and examine their associations with incident MACE in middle‐aged and older Chinese adults. Methods: This prospective cohort study included 9597 participants aged 45 years or older and free of cardiovascular disease at baseline from the China Health and Retirement Longitudinal Study. Among them, 6405 participants with biomarker measurements available in both 2011 and 2015 were included in the two‐point change pattern analysis. Group‐based trajectory modeling was used to identify two‐point change pattern groups for LDL‐C and log‐transformed hs‐CRP. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs), with adjustment for potential confounders including lipid‐lowering medication use. Results: Over a median follow‐up of 9.00 years, 2248 participants (23.4%) developed MACE. Higher baseline hs‐CRP levels were associated with increased MACE risk, with a significant association observed for the fourth quintile versus the first quintile (HR = 1.19, 95% CI: 1.04–1.36). In the two‐point change pattern analysis, the High baseline, decreasing log‐hsCRP group showed a lower HR estimate for MACE than the Low baseline, increasing group, although this association did not reach conventional statistical significance (HR = 0.82, 95% CI: 0.67–1.01, p = 0.06). Neither baseline LDL‐C levels nor LDL‐C two‐point change pattern groups were significantly associated with MACE after full multivariable adjustment. Having one elevated biomarker (LDL‐C Q5 or hs‐CRP Q5) was associated with increased MACE risk (HR = 1.11, 95% CI: 1.02–1.21) compared with having neither elevated. Conclusion: Baseline hs‐CRP showed a stronger association with MACE than LDL‐C after comprehensive adjustment. A decrease in hs‐CRP from a high baseline level was associated with a lower HR estimate for MACE, although this finding was not statistically significant. These results support the relevance of inflammatory status in cardiovascular risk assessment, while LDL‐C monitoring remains a cornerstone of cardiovascular prevention.

  • Oral cascade–responsive nanomedicine to disrupt macrophage–neutrophil crosstalk for intestinal barrier repair

    by Yuanyuan Cheng, Dandan Wu, Qiyao Liu, Yongkang Liu, Xiaoyu Han, Jinsong Cao, Yuhan Wang, Yang Liu, Yujun Shen, Yinsong Wang, et al.

  • Open Access

    Thromboxane receptor activation in dendritic cells mitigates sepsis by suppressing S100a8/a9-mediated neutrophil recruitment

    by Ronglu Du, Ting Pan, Yuhan Wang, Yan Fan, Qian Liu, Xixi Tao, Shumin Guo, Danyang Tian, Roger S.-Y. Foo, Keliang Xie, et al.

    Dendritic cells (DCs) regulate both innate and adaptive immunity during sepsis. Prostaglandins (PGs), small lipid molecules derived from arachidonic acid via COX enzymes, are crucial regulators of immune homeostasis and inflammation. However, their role in sepsis pathogenesis remains poorly defined. In this study, we identified a significant negative correlation between DC depletion and disease severity in patients with sepsis. Thromboxane (TX) A2 receptor (TP) expression was markedly reduced in the blood DCs of patients with sepsis. Patients with low DC-TP expression presented increased blood neutrophil counts and worsened disease severity. In murine models of sepsis induced by cecal ligation and puncture and lipopolysaccharide challenge, DC-specific TP deficiency exacerbated sepsis by promoting S100a8/a9-mediated neutrophil recruitment and, subsequently, neutrophil extracellular trap (NET) formation and lung injury. Genetic and pharmacological inhibition of the S100a8/a9-TLR4 axis protected TP-deficient mice from fatal sepsis. Mechanistically, TP signaling suppressed S100a8/a9 expression in DCs via PKCδ-Stat1 signaling, thereby restricting neutrophil infiltration and NET formation. Finally, the targeted activation of TP in DCs via the nanodrug DCpep-U-46619 effectively alleviated sepsis-induced lung injury in mice. These findings establish TP as a critical immunoregulatory receptor in DCs, highlighting its potential as a therapeutic target for sepsis.


  • Differential Impact of Recruited and Resident Macrophages on Hypoxia-Induced Pulmonary Hypertension

    by Shumin Guo, Ting Pan, Xiaojie Yan, Yuanyuan Cheng, Ronglu Du, Qian Liu, Yongle Huang, Yujuan Zhuo, Yan Zhao, Danyang Tian, et al.

    BACKGROUND: Pulmonary interstitial macrophages can be divided into 2 distinct subsets with different origins: resident macrophages (resMФs) and recruited macrophages (recMФs). However, their specific roles in pulmonary arterial hypertension remain unclear. METHODS: Bone marrow transplantation, the DT (diphtheria toxin) receptor system, and genetically modified murine models were utilized to explore how key TFs (transcription factors) regulate phenotype alterations in pulmonary resMФs and recMФs in an SU5416/hypoxia murine model of pulmonary hypertension (PH). Therapeutic approaches included DNA aptamer–based proteolysis-targeting chimera and small interfering RNA–loaded lipid nanoparticle for treating SU5416/hypoxia–exposed rats. RESULTS: Depletion of either resMФs or recMФs using DT treatment significantly reduced SU5416/hypoxia–induced PH in mice. Pulmonary recMФs exhibited a proinflammatory phenotype during PH, driven by the TF Hic1 (hypermethylated in cancer 1). Bone marrow transplantation with Hic1 −/− recMФs ameliorated PH in mice. Hic1 enhanced proinflammatory gene transcription by inhibiting Sirt1 (sirtuin 1)-mediated H3K9ac (histone H3 lysine 9 acetylation) deacetylation in the promoter regions. In contrast, pulmonary resMФs demonstrated a profibrotic transcriptome characterized by upregulation of MMP genes that are, in turn, regulated by Prrx2 (paired-related homeobox 2). Prrx2 deletion in resMФs protected against PH in mice by reducing perivascular fibrosis. Simultaneously targeting Prrx2 and Hic1 in macrophages significantly alleviated SU5416/hypoxia–induced PH in rats. CONCLUSIONS: The differential roles of pulmonary resMФs and recMФs in pulmonary vascular remodeling highlight novel therapeutic targets for pulmonary arterial hypertension treatment, specifically through inhibition of Hic1 and Prrx2 in macrophages.


  • Open Access

    Sympathetic Activation Promotes Kidney Fibrosis in Mice via Macrophage‐Derived N2ICD‐Enriched Extracellular Vesicles

    by Huiwen Ren, Yayan Hou, Chengsen Mu, Yinghong Zheng, Yuanyang Wang, Shumin Guo, Lu Wang, Wenlong Shang, Zhuming Yin, Cheng Dong, et al.

    Persistent overactivation of the renal sympathetic nervous system drives kidney inflammation and fibrosis. Macrophages contribute to fibrogenesis by secreting various pro‐fibrogenic mediators. However, whether the sympathetic nervous system regulates renal fibrosis by modulating macrophage‐fibroblast interaction remains unclear. Here, it is demonstrated that norepinephrine (NE)‐treated macrophages promoted renal fibroblast activation through the transfer of Notch2 intracellular domain (N2ICD)‐enriched extracellular vesicles (EVs) to fibroblasts. Depletion of macrophage mitigated kidney fibrosis in mice subjected to unilateral nephrectomy plus contralateral ischemia‐reperfusion injury (Npx‐IRI) or repeated low‐dose cisplatin (RLDC) regimen. Macrophage‐specific deletion of Notch2 or α2B‐adrenoceptor disrupted N2ICD‐EV formation and protected mice from kidney fibrosis. Mechanistically, N2ICD stabilized Smad3 by preventing its ubiquitin‐dependent degradation, thereby enhancing TGF‐β signaling to promote fibroblast activation. These findings establish a sympathetic nerve‐macrophage‐fibroblast axis in renal fibrosis and highlight macrophage‐specific Notch2 inhibition as a potential therapeutic strategy.


  • Open Access

    Deletion of EP3 prostaglandin receptor in murine macrophages aggravates diet-induced obesity by suppressing SPARC

    by Wenlong Shang, Yinxiu Li, Lu Wang, Jiao Liu, Huiwen Ren, Qian Liu, Shumin Guo, Yuhong Wang, Yubo Ma, Tianyi You, et al.

    Macrophages are primary immune cells involved in obesity-triggered chronic low-grade inflammation in adipose tissues. Prostaglandin E2 (PGE 2 ), mainly generated from macrophages, can regulate adipose tissue remodeling, yet the underlying mechanisms are not fully understood. Here, we observed that PGE 2 receptor subtype 3 (EP3) was remarkably downregulated in adipose tissue macrophages from high-fat diet (HFD)-fed mice and patients with obesity. Notably, macrophage-specific deletion of EP3 exacerbated HFD-induced fat expansion, whereas EP3α isoform overexpression in macrophages alleviated obesity phenotypes. Further, EP3 deficiency suppressed secretion of anti-adipogenic matricellular protein SPARC from macrophages. SPARC deletion in macrophages abrogated the protection of EP3-overexpression against diet-induced obesity. Mechanistically, EP3 activation promoted SPARC expression by suppressing DNA methylation in macrophages through a PKA-Sp1-Dnmt1/3a signaling cascade. Finally, EP3 agonist treatment ameliorated HFD-induced obesity in mice. Thus, EP3 inhibits adipogenesis through promoting release of SPARC from macrophages, suggesting a novel therapeutic target for diet-induced obesity.


  • Open Access

    Quantitative evaluation of IVL: based on the tunica media gypsum calcification model and a prospective animal study

    by Zongwei Liu, Chuang Xu, Bin Zhao, Jiayin Guo, Jingzhong Song, Jiaxue Bi, Yujun Shen, Xiangchen Dai

    Background: Intravascular lithotripsy (IVL), an emerging adjunctive therapeutic modality, demonstrates potential in managing severely calcified lesions. However, its quantitative efficiency in disrupting calcifications with different characteristics, as well as the degree of damage to normal arteries, remains to be confirmed.Objectives: This study aimed to: (i) quantitatively evaluate the efficacy of IVL in disrupting different types of calcifications, and (ii) assess the impact of IVL on normal vascular structures.Methods: The gypsum models with different thicknesses and eccentricities were used to evaluate the effectiveness of IVL in disrupting calcifications with different characteristics. In vivo experiments involved iliofemoral arterial segments of nine Yorkshire experimental swine that were subjected to IVL and PTA working balloons, respectively. In vitro effectiveness of IVL was evaluated using the number of disrupted gypsum rings based on the gypsum models. In vivo effectiveness and safety of IVL were evaluated by digital subtraction angiography (DSA), light microscopy, and immunofluorescence staining based on the experimental swine at 0, 7, and 28 days.Results: The gypsum models revealed that the 1.04:1 oversized IVL working balloon could provide an optimal tightness between the balloon and the artery wall. The DSA imaging results showed that IVL significantly increased the immediate treated artery's diameter at +27.12 ± 10.23% compared to the PTA working balloon at +13.72 ± 7.66% in all experimental animals (n = 9, p = 0.0063). The imaging results revealed that IVL treatment significantly alleviated the lumen loss rate of treated arteries compared to the PTA working balloon at 7 (1.10 ± 0.58% vs. 3.27 ± 0.66%) and 28 (4.90 ± 1.60% vs. 10.10 ± 1.53%) days postoperatively (p < 0.05). Histopathological analysis showed the IVL treatment did not increase the inflammatory status, synthesis of collagen, and other artery wall characteristics at 0, 7, and 28 days postoperatively. The immunofluorescence staining results revealed that IVL treatment did not significantly decrease the proportion of smooth muscle cells and endothelial cells in the treated artery.Conclusion: Our experiment revealed that the IVL device has good therapeutic effects on different characteristics of calcifications hiding in the tunica media and with good biological safety.

  • Notch2 Inhibition and Kidney Cyst Growth in Autosomal Dominant Polycystic Kidney Disease

    by Huiwen Ren, Chengsen Mu, Yuhan Wang, Yuanyuan Cheng, Yayan Hou, Yizhe Li, Na Liu, Zhuming Yin, Hui Xiong, Yupeng Chen, et al.

    Key Points: Notch2 activation promotes kidney cyst growth. Silencing Notch2 ameliorated cyst growth in mice with autosomal dominant polycystic kidney disease. Background: Notch signaling, a conserved mechanism of cell-to-cell communication, plays a crucial role in regulating cellular processes, such as proliferation and differentiation, in a context-dependent manner. However, the specific contribution of Notch signaling to the progression of polycystic kidney disease (PKD) remains unclear. Methods: We investigated the changes in Notch signaling activity (Notch1–4) in the kidneys of patients with autosomal dominant PKD (ADPKD) and two ADPKD mouse models (early and late onset). Multiple genetic and pharmacologic approaches were used to explore Notch2 signaling during kidney cyst formation in PKD. Results: Notch2 expression was significantly increased in the kidney tissues of patients with ADPKD and ADPKD mice. Targeted expression of Notch2 intracellular domain in renal epithelial cells resulted in cyst formation and kidney failure in neonatal and adult mice. Mechanistically, Notch2/Hey2 signaling promoted renal epithelial cell proliferation by driving the expression of the E26 transformation–specific homologous factor (Ehf). Depletion of Ehf delayed Notch2 intracellular domain overexpression–induced cyst formation and kidney failure in mice. A gain-of-function mutation in exon 34 of NOTCH2 (c.6426dupT), which caused PKD in patients with Hajdu–Cheney syndrome, accelerated cell growth in cultured human renal epithelial cells by activating HEY2/EHF signaling. Finally, ablation of Notch2 or treatment of a kidney-targeting nanoparticle carrying the liposome/Notch2–small interfering RNA complex, significantly suppressed kidney cyst growth in early-onset ADPKD mice. Conclusions: Notch2 signaling promoted kidney cyst growth, partially by upregulating Ehf expression.


  • Open Access

    Targeting the EP2 receptor ameliorates inflammatory bowel disease in mice by enhancing the immunosuppressive activity of Treg cells

    by Chenchen Wang, Tingting Yu, Yuexin Wang, Mengtong Xu, Jingjing Wang, Yan Zhao, Qiangyou Wan, Lu Wang, Jie Yang, Jie Zhou, et al.